Physician profile
Embril Edwards
NPI 1982101846
$4,255.46
in general payments reported to CMS, 2019-2025
32 companies · $1,201 in 2025
The $1,201 reported for 2025 was more than what 90% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $93.80 · 2021: $268 · 2022: $926 · 2023: $931 · 2024: $836 · 2025: $1,201.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,968.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,967.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $782.23 | 2021-2025 | Qulipta, Vraylar, Dalvance |
| Pfizer INC. | $556.85 | 2021-2025 | |
| Glaxosmithkline, LLC. | $418.00 | 2022-2025 | Trelegy Ellipta, Shingrix, Bexsero |
| Lilly USA, LLC | $341.10 | 2019-2025 | Mounjaro, Jardiance |
| Otsuka America Pharmaceutical, INC. | $270.90 | 2022-2025 | Rexulti |
| Merck Sharp & Dohme LLC | $218.36 | 2021-2024 | Verquvo, Belsomra, Steglatro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $210.25 | 2021-2025 | Xifaxan |
| Novo Nordisk INC | $168.95 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $153.35 | 2021-2025 | Farxiga, Evusheld, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $142.23 | 2025 | |
| Amgen INC. | $139.38 | 2022-2025 | Repatha, Otezla, Repatha |
| Exact Sciences Corporation | $120.98 | 2023-2025 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $82.91 | 2023-2025 | |
| Ardelyx, INC. | $79.67 | 2024-2025 | Ibsrela |
| Boehringer Ingelheim Pharmaceuticals, INC. | $72.02 | 2021-2025 | Jardiance |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $68.86 | 2021-2023 | Trintellix |
| Biohaven Pharmaceutical Holding Company LTD. | $59.78 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $53.21 | 2025 | Caplyta |
| Jazz Pharmaceuticals INC. | $39.97 | 2021 | |
| Phathom Pharmaceuticals, INC. | $38.05 | 2024 | Voquezna |
| Inspire Medical Systems, INC. | $35.74 | 2025 | Inspire |
| Biogen, INC. | $31.40 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $27.77 | 2021-2023 | Eliquis |
| Corcept Therapeutics | $20.74 | 2024 | Korlym |
| Biohaven Pharmaceuticals, INC. | $19.95 | 2021 | |
| Genzyme Corporation | $18.56 | 2023 | |
| Vanda Pharmaceuticals INC. | $16.93 | 2025 | Fanapt |
| Axsome Therapeutics, INC. | $16.20 | 2024 | Auvelity |
| Daiichi Sankyo INC. | $13.77 | 2022 | |
| Depuy Synthes Sales INC. | $13.21 | 2024 | Orthovisc |
| Kowa Pharmaceuticals America, INC. | $12.10 | 2022 | |
| Seqirus USA INC | $12.04 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Embril Edwards listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.